Nasdaq:US$16.68 (-0.98) | HKEX:HK$26.50 (-0.15) | AIM:£2.69 (-0.19)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 17 Feb 2009

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

1 items
a090217